Phio Pharmaceuticals

Region Nordamerika
ISIN US71880W2044
Sektor Biotechnologie

Phio Pharmaceuticals is focused on developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYLTM) therapeutic platform. Immunotherapies harness our immune system to restore surveillance of tumors that evade detection – a potential curative medicine. INTASYLTM therapeutics can be used as a standalone treatment or in combination with other modalities.

Artikel über Phio Pharmaceuticals

Titel Autor Datum
In Wahrheit 100 Mal so viel wert?
sharedeals vor ungefähr 3 Jahren